Compare BGC & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BGC | KRYS |
|---|---|---|
| Founded | 1945 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 9.6B |
| IPO Year | 1999 | 2017 |
| Metric | BGC | KRYS |
|---|---|---|
| Price | $12.19 | $336.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $297.60 |
| AVG Volume (30 Days) | ★ 2.5M | 216.7K |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | ★ 0.72% | N/A |
| EPS Growth | 24.00 | ★ 128.00 |
| EPS | 0.31 | ★ 3.62 |
| Revenue | ★ $2,941,460,000.00 | $389,130,000.00 |
| Revenue This Year | $22.26 | $38.74 |
| Revenue Next Year | $7.03 | $32.53 |
| P/E Ratio | ★ $38.68 | $93.58 |
| Revenue Growth | 29.99 | ★ 33.94 |
| 52 Week Low | $8.27 | $158.08 |
| 52 Week High | $12.89 | $382.54 |
| Indicator | BGC | KRYS |
|---|---|---|
| Relative Strength Index (RSI) | 60.57 | 42.84 |
| Support Level | $11.59 | $318.87 |
| Resistance Level | $12.43 | $371.16 |
| Average True Range (ATR) | 0.36 | 10.44 |
| MACD | -0.01 | -2.67 |
| Stochastic Oscillator | 73.51 | 10.96 |
BGC Group Inc is a brokerage and financial technology company that serves financial markets, energy, and commodities markets. Its service and product offerings include brokerage for a wide range of financial products, including fixed income, equities, commodities, derivatives, and real estate, software solutions for trading platforms, clearing, trade execution, and other back-office services. Its clients mostly include banks, financial institutions, and corporate clients. BGC operates in one reportable segment, which is providing brokerage services. Geographically, the company generates a majority of its revenue from Europe, the Middle East and Africa (EMEA), followed by the Americas and the Asia-Pacific region.
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.